A detailed history of Met Life Investment Management, LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 21,504 shares of TARS stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,504
Previous 21,504 -0.0%
Holding current value
$1 Million
Previous $584,000 21.06%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.17 - $38.73 $150,113 - $230,985
5,964 Added 38.38%
21,504 $584,000
Q1 2024

May 14, 2024

BUY
$19.61 - $39.22 $304,739 - $609,478
15,540 New
15,540 $564,000
Q4 2023

Feb 14, 2024

BUY
$12.98 - $20.73 $35,980 - $57,463
2,772 Added 21.71%
15,540 $314,000
Q3 2023

May 09, 2024

BUY
$14.75 - $24.62 $30,886 - $51,554
2,094 Added 19.62%
12,768 $226,000
Q2 2023

Apr 29, 2024

BUY
$11.57 - $19.63 $147,725 - $250,635
12,768 New
12,768 $230,000
Q2 2023

Aug 10, 2023

BUY
$11.57 - $19.63 $24,227 - $41,105
2,094 Added 19.62%
12,768 $230,000
Q1 2023

May 09, 2024

BUY
$11.92 - $16.27 $127,234 - $173,665
10,674 New
10,674 $134 Million
Q2 2022

May 10, 2024

BUY
$11.08 - $19.08 $118,267 - $203,659
10,674 New
10,674 $155,000
Q2 2022

Mar 22, 2023

BUY
$11.08 - $19.08 $82,257 - $141,649
7,424 Added 228.43%
10,674 $155,000
Q2 2022

Aug 11, 2022

BUY
$11.08 - $19.08 $118,267 - $203,659
10,674 New
10,674 $156,000
Q1 2021

May 14, 2021

SELL
$27.37 - $47.25 $88,952 - $153,562
-3,250 Closed
0 $0
Q4 2020

May 24, 2024

SELL
$19.17 - $49.62 $235,599 - $609,829
-12,290 Reduced 79.09%
3,250 $134,000
Q4 2020

Jun 22, 2023

SELL
$19.17 - $49.62 $142,318 - $368,378
-7,424 Reduced 69.55%
3,250 $134,000
Q4 2020

Mar 22, 2023

SELL
$19.17 - $49.62 $142,318 - $368,378
-7,424 Reduced 69.55%
3,250 $134,000
Q4 2020

Feb 16, 2021

BUY
$19.17 - $49.62 $62,302 - $161,265
3,250 New
3,250 $134,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.24B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.